Case Report: Amiodarone-triggered refractory ventricular fibrillation storm in septic cardiomyopathy with pre-existing QT prolongation: termination using lidocaine and anisodamine - Top-Institutions - MDSpire

Case Report: Amiodarone-triggered refractory ventricular fibrillation storm in septic cardiomyopathy with pre-existing QT prolongation: termination using lidocaine and anisodamine

  • By

  • Min Wu

  • Lutao Xie

  • Pin Lan

  • Meisong Chen

  • June 10, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic Heart, Vascular & Thoracic Institute
    Cleveland Clinic Heart, Vascular & Thoracic Institute

    Cleveland, Ohio

    Key Differentiators

    • Cardiology
    • Electrophysiology

  • #2

    Mayo Clinic – Windland Smith Rice Genetic Heart Rhythm Clinic
    Mayo Clinic – Windland Smith Rice Genetic Heart Rhythm Clinic

    Rochester, Minnesota

    Key Differentiators

    • Cardiology
    • Genetic Heart Rhythm

  • #3

    St. Georg Hospital
    St. Georg Hospital

    Hamburg, Germany

    Key Differentiators

    • Electrophysiology

  • #4

    Heart Centre Bad Neustadt
    Heart Centre Bad Neustadt

    Bad Neustadt, Germany

    Key Differentiators

    • Electrophysiology

  • #5

    German Heart Center Munich
    German Heart Center Munich

    Munich, Germany

    Key Differentiators

    • Electrophysiology

Original Source(s)

Case Report: Amiodarone-triggered refractory ventricular fibrillation storm in septic cardiomyopathy with pre-existing QT prolongation: termination using lidocaine and anisodamine

  • by Min Wu, Lutao Xie, Pin Lan, Meisong Chen

  • June 10, 2026

Related Content

AI-Powered Resting 12-Lead Electrocardiogram Algorithm for Predicting Low Peak Oxygen Consumption: Development and Validation Study

Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study

Association of achieved LDL-C levels with global coagulability and clinical outcomes in patients with acute coronary syndrome receiving PCSK9 inhibitors: a prospective cohort study